To evaluate the efficacy and safety of Shensong Yangxin (SSYX) in patients with bradycardia arrhythmias, a randomized, doubleblind,\r\nand placebo-controlled study was conducted. Patients with bradycardia were randomly assigned to receive either SSYX (trial\r\ngroup, ?? = 115) or placebo (control group, ?? = 104) for 4 weeks. ECG, 24-hour continuous ECG recording, echocardiography, and\r\nhepatic and renal function were evaluated at baseline and after treatment. Results showed that the average heart rate, the fastest\r\nheart rate, and the lowest heart rate in the trial group were all significantly higher than those in the control group at the end of\r\ntreatment (?? < 0.05 or 0.01, resp.). Compared with pretreatment, the average heart rate, the fastest heart rate, and the lowest heart\r\nrate in the trial group all increased significantly after treatment (?? < 0.05 or 0.01, resp.). Both the efficacy and the symptomscores in\r\nthe trial group were significantly better than those in the control group after treatment (both having ?? < 0.01). No severe adverse\r\neffects were reported. In conclusion, SSYX treatment significantly increased the heart rate in patients with bradycardia without\r\nsevere side effects. The exact mechanisms remain to be further explored.
Loading....